This week in therapeutics

Indication	Target/marker/pathway	Summary	Licensing status	Publication and contact information
Cancer				
Breast cancer; prostate cancer	Insulin-like growth factor-1 receptor (IGF1R; CD221); dishevelled segment polarity protein 3 (DVL3)	<p>Studies <i>in vitro</i> and in human samples suggest IGF1R inhibitors could be most effective in patients with cancer who show suppressed DVL3 expression. Resistance and lack of biomarkers have hampered the development of IGF1R inhibitors in clinical trials. In resistant human breast and prostate cancer cells treated with an IGF1R inhibitor, <i>DVL3</i>-targeting siRNA decreased cell viability compared with control siRNA. In samples from patients treated with anti-IGF1R mAbs, low <i>DVL3</i> expression correlated with increased disease control and survival. Next steps could include evaluating <i>DVL3</i> expression in additional patient cohorts. Amgen Inc. and Takeda Pharmaceutical Co. Ltd. have ganitumab, a human mAb antagonist of IGF1R, in Phase III testing to treat pancreatic cancer and Phase II trials to treat various other cancers. Astellas Pharma Inc. has the IGF1R inhibitor linsitinib in Phase III testing to treat adenocarcinoma. The compound also is in Phase II or earlier trials to treat other cancers. At least 11 other companies have IGF1R-targeting compounds in Phase II or earlier testing to treat various cancers.</p> <p>SciBX 7(38); doi:10.1038/scibx.2014.1119 Published online Oct. 2, 2014</p>	Patent and licensing status undisclosed	<p>Gao, S. <i>et al. Cancer Res.</i>; published online Aug. 28, 2014; doi:10.1158/0008-5472.CAN-14-0806 Contact: Valentine M. Macaulay, University of Oxford, Oxford, U.K. e-mail: valentine.macaulay@imm.ox.ac.uk</p>